J&J touts success of nipocalimab in two rare disease trials
Pharmaceutical Technology
FEBRUARY 6, 2024
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
Tue.Feb 06, 2024
130 
Cystic fibrosis patients ask DPIIT to allow local manufacturing of CFTR modulators to bring down price
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 6, 2024
Patients of cystic fibrosis (CF) and their relatives have requested the Department for Promotion of Industry and Internal Trade (DPIIT) to take steps to provide CF drugs at an affordable cost using the provisions of the Patents Act, 1970, considering that the drugs at present cost anywhere from Rs. 21 lakh to Rs. 2.66 crore.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alternative therapies are needed to combat the impending threat of AMR
Pharmaceutical Technology
FEBRUARY 6, 2024
The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.
US Woman Receives Revolutionary Brain Implant For OCD And Epilepsy
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 6, 2024
American Amber Pearson used to wash her hands until they bled, terrified by the idea of contamination from everyday items, a debilitating result of her obsessive compulsive disorder (OCD).
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Health Canada approves Chiesi’s MYALEPTA for lipodystrophy
Pharmaceutical Technology
FEBRUARY 6, 2024
Health Canada has approved Chiesi Global Rare Diseases’ MYALEPTA as a treatment for individuals with lipodystrophy, an ultra-rare condition.
Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery
Bio Pharma Dive
FEBRUARY 6, 2024
The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Lilly sales surge on obesity, diabetes drug demand
Bio Pharma Dive
FEBRUARY 6, 2024
The company also reported trial results suggesting tirzepatide, the drug Lilly now sells as Mounjaro and Zepbound, could treat a common liver disease.
Study reveals blood test can pinpoint cause of brain injury in newborns
Pharma Times
FEBRUARY 6, 2024
Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year
Eisai falls behind on Leqembi patient goal
Bio Pharma Dive
FEBRUARY 6, 2024
The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.
Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline
Pharmaceutical Technology
FEBRUARY 6, 2024
Pending a successful acquisition, Novartis will obtain pelabresib for myelofibrosis and tulmimetostat for solid tumours or lymphomas.
MorphoSys to sell to Novartis for $2.9B, offloads cancer drug to Incyte
Bio Pharma Dive
FEBRUARY 6, 2024
The deals hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.
Rani reports positive data for non-injectable Stelara biosimilar
Pharmaceutical Technology
FEBRUARY 6, 2024
RT-111 could offer an alternative dosing regimen for patients with psoriasis and other conditions compared to injectable biologics.
February 6, 2024: Racial and Ethnic Minority Injury Survivors See Greater Improvements in PTSD Symptoms in the TSOS Study
Rethinking Clinical Trials
FEBRUARY 6, 2024
Injury survivors from racial and ethnic minority groups experienced greater improvements than White injury survivors in their posttraumatic stress disorder (PTSD) symptoms after receiving a stepped collaborative care intervention. This was the finding of a secondary analysis of data from the Trauma Survivors Outcomes and Support (TSOS) study, an NIH Pragmatic Trials Collaboratory Trial.
China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor
Pharmaceutical Technology
FEBRUARY 6, 2024
The China NMPA has granted clearance for the investigational new drug (IND) application of Guangzhou Fermion Technology’s FZ007-119.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Already rolling in diabetes and obesity, Eli Lilly touts tirzepatide's midstage MASH win
Fierce Pharma
FEBRUARY 6, 2024
In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.< | Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease with a massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect.
Incyte acquires global rights to MorphoSys’ tafasitamab
Pharmaceutical Technology
FEBRUARY 6, 2024
Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.
AstraZeneca brings its cell therapy ambitions to Maryland with $300M plant investment, 150 planned hires
Fierce Pharma
FEBRUARY 6, 2024
Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. | AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs.
Silence announces $120m private placement for depositary shares
Pharmaceutical Technology
FEBRUARY 6, 2024
Silence Therapeutics has announced a private placement of its 5,714,286 American depositary shares (ADS) priced at $21 each.
A clearer harmony and attractiveness for EU Clinical Trials Regulation
pharmaphorum
FEBRUARY 6, 2024
For the latest episode of the pharmaphorum podcast, web editor Nicole Raleigh sat down with Chris Bamford, director of clinical trial regulatory management at IQVIA, and Shirley Rutter, associate director and strategic quality lead of global quality management at IQVIA Biotech.
The Correlation Between a New York State Law Repeal and Vaccine Coverage in Schools
Pharmaceutical Commerce
FEBRUARY 6, 2024
A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?
Cedars-Sinai mental health app launches on Apple Vision Pro
pharmaphorum
FEBRUARY 6, 2024
Right after the official launch of the new Apple Vision Pro mixed reality headset, Cedars-Sinai has launched a generative artificial intelligence (genAI) app that will use the technology to provide mental health support for patients.
Medable's enhanced electronic consent making patients feel more human and less like study subjects
Outsourcing Pharma
FEBRUARY 6, 2024
Results from a new research project have been announced by technology provider Medable on the enhanced electronic informed consent (elC) in clinical trials.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Changing Faces: Pharma and biotech hires from January 2024
pharmaphorum
FEBRUARY 6, 2024
Stay updated with the latest news on hiring trends in the pharmaceutical and biotech industries. Learn about the companies and professionals making waves in the field from January 2024 in a new instalment of Changing Faces.
New Year, New Aspirations
Pharmaceutical Commerce
FEBRUARY 6, 2024
Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.
More pharma M&A as Novartis snaps up MorphoSys for $2.9bn
pharmaphorum
FEBRUARY 6, 2024
Novartis has agreed to buy Germany's MorphoSys in a transaction that values the cancer-focused biotech at $2.
Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gains
Fierce Pharma
FEBRUARY 6, 2024
Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP | Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pfizer partners American Cancer Society on health equity
pharmaphorum
FEBRUARY 6, 2024
A $15m initiative between Pfizer and the American Cancer Society aims to tackle unequal access to care in the US.
How Good Measures Is Revolutionizing Health with its Good Food Prescription Program
XTalks
FEBRUARY 6, 2024
Good Measures has made a significant leap forward by showcasing the positive outcomes of its Good Food Prescription program in its first year. This program, designed to combat diet-related conditions, combines expert clinical coaching, personalized meal planning and medically tailored grocery deliveries in partnership with Instacart. The Emergence of Good Measures Founded with a vision to revolutionize the intersection of nutrition and health management, Good Measures has established itself as a
Metagenomi prices IPO and NeOnc joins list of hopefuls
pharmaphorum
FEBRUARY 6, 2024
Gene-editing startup Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings
RWE’s Impact on Product Lifecycle for Biopharma Startups
Pharma Mirror
FEBRUARY 6, 2024
By Barbara Arone, Vice President, Real World Solutions, IQVIA The use of real-world evidence (RWE) in the development of pharmaceutical treatments has grown exponentially in the past 10 years, fueled by availability of higher quality data, trial competitiveness and growing investments in personalized and rare disease treatments. It has transformed from a “nice-to-have” into a “must-have” part of the evidence package, helping to contextualize clinical research and improve treatment understanding.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content